What Xeris Biopharma Doubters Overlooked

XP-8121, Xeris Biopharma’s once weekly levothyroxine candidate, moved from concept to a clearly mapped Phase 3 plan during the period, giving holders something very specific to track beyond the existing endocrine portfolio. Investors who held Xeris Biopharma from the start of the year are up 38.4%, including dividends. If you were weighing a purchase on 1 January 2026, what had to be true in your mind about Recorlev, Gvoke and XP-8121 for that gain to feel reasonable?

Xeris Biopharma has already moved. See which of 34 high quality undervalued stocks still trade below our estimates.

The Argument Xeris Biopharma Investors Were Really Having

The shares cost US$7.85 at the start of the period, so anyone looking at Xeris Biopharma then had to decide which story felt more plausible.

The bullish narrative pointed to a Fair Value of US$9, a rough guide to what that camp thought the stock could be worth if its assumptions played out, built on revenue growth of 21.5% and profit margins reaching 19.2% within three years.

The bearish view anchored on a Fair Value of US$6 and treated rising healthcare costs, tighter regulation, and reliance on Recorlev and Gvoke as risks that could limit margins to 5.2% and still require a high 67.3x future P/E to justify that lower target.

What The Results Changed For Xeris Biopharma

Quarterly updates from Xeris Biopharma gave both sides new material. Recorlev led a 38.3% rise in Q1 2026 revenue to US$83.1 million and helped produce a US$2.2 million profit, which leaned toward the optimistic case on demand. Yet by Q2 2026, revenue of US$92.1 million sat alongside a much larger US$31.1 million loss and a net margin that fell to 33.8%, so profitability progress clearly lagged. Overall, the evidence cut both ways.

The key lesson is simple. When a story rests on Recorlev, Gvoke and XP-8121 improving margins, it is important to track net income and net margin each quarter and see whether higher sales actually convert into lasting profitability.

What Today's Xeris Biopharma Price Already Assumes

Xeris Biopharma now trades at US$10.17 from the start of the year, and the selected Narrative places its Fair Value below that level. The gap is tied less to headline growth and more to whether spending on XP-8121 and the enlarged commercial engine earns its keep.

A buyer today effectively assumes XP-8121 eventually supports that higher cost base and validates the endocrinology focus. The question is how the specific risks around payer pressure, Gvoke volumes and XP-8121 clinical and launch execution weigh on that expectation.

"The plan to scale an endocrinology focused commercial engine around Recorlev, Gvoke and Keveyis requires substantially higher selling effort, and management now expects SG&A to rise by about US$50 million in 2026 versus 2025. If Gvoke or any other product underutilises this larger footprint, the result could be weaker SG&A efficiency and softer operating margins than the current trajectory implies."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Where Xeris Demand Might Echo

Xeris Biopharma leans on endocrine demand, but your research does not need to stop there.

Chronic metabolic conditions create long treatment timelines and pressure for better outcomes. That pressure also shapes another large drug maker building cardiometabolic therapies.

Instead of endocrine replacement, this group concentrates on diabetes, obesity and related complications. It experiments with new drug formats, combinations and access programs.

The goal is to widen treatment options across similar chronic conditions.

If those therapies gain real world use, investors might see a broader toolkit serving many of the same patients Xeris reaches from a different angle.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 17% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com